StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > Questions for this Presentation

<< Previous

Bullboard Posts

Next >>

Comment by davewhoon Apr 22, 2021 8:46pm

120 Views

Post# 33052975

RE:RE:RE:RE:RE:Questions for this Presentation

Pretty sure James said today that they expect covid testing to continue well into next year 2022. As of today the stats say only 26% of the US is fully vaccinated. With virus variants appearing at an alarming rate vaccination rates could prove to be meaningless. We may need to be tested and vaccinated yearly just like the flu. Especially for travellers.

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record